AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28276510 — intervention group
Group type: EXPERIMENTAL
Intervention: Social observation during the ultimatum game (UG)
Number of subjects: 32
Study 28276510 — intervention group
Group type: COMPARATOR
Intervention: No social observation during the ultimatum game (UG)
Number of subjects: 32
Study 26037286 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct oral anticoagulants (DOACs) in addition to antiplatelet therapy
Number of subjects: 46782
Study 26037286 — intervention group
Group type: EXPERIMENTAL
Intervention: PAR-1 antagonists in addition to antiplatelet therapy
Number of subjects: 46782
Study 26037286 — intervention group
Group type: COMPARATOR
Intervention: Antiplatelet therapy alone
Number of subjects: 46782
Study 23515265 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily median estimated pulmonary artery diastolic pressures (ePAD)
Number of subjects: 378
Study 23515265 — intervention group
Group type: EXPERIMENTAL
Intervention: Average median ePAD calculated over the whole follow-up period
Number of subjects: 378
Study 21757376 — intervention group
Group type: EXPERIMENTAL
Intervention: GIN therapy (high-dose insulin at 5 mU/kg/min during surgery)
Number of subjects: 40
Study 21757376 — intervention group
Group type: EXPERIMENTAL
Intervention: GIN therapy
Number of subjects: 40
Study 21757376 — intervention group
Group type: COMPARATOR
Intervention: Control group (insulin on a sliding scale aiming at normoglycemia)
Number of subjects: 40
Study 19539104 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation of alendronate sodium 70 mg
Number of subjects: 23
Study 19539104 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation of alendronate sodium 70 mg
Number of subjects: 23
Study 17603694 — intervention group
Group type: EXPERIMENTAL
Intervention: Low power radiofrequency electromagnetic radiation (RF)
Number of subjects: 40
Study 17603694 — intervention group
Group type: COMPARATOR
Intervention: Transcutaneous electrical nerve stimulation (TENS)
Number of subjects: 40
Study 15193907 — intervention group
Group type: EXPERIMENTAL
Intervention: Peeled sweeties supplemented diet (EG1)
Number of subjects: 66
Study 15193907 — intervention group
Group type: EXPERIMENTAL
Intervention: Peeled sweeties supplemented diet (EG2)
Number of subjects: 66
Study 15193907 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 66
Study 11405503 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy
Number of subjects: 74
Study 11405503 — intervention group
Group type: COMPARATOR
Intervention: Control (no thrombolytic therapy)
Number of subjects: 74
Study 9989882 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral blood stem cell (PBSC) collection with mobilising chemotherapy (cyclophosphamide, etoposide, doxorubicin, cytosine arabinoside) and G-CSF, total of 47 courses.
Number of subjects: 37
Study 9989882 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy with autologous stem cell rescue (21 of 37 patients).
Number of subjects: 37
Study 9989882 — intervention group
Group type: COMPARATOR
Intervention: PBSC group compared to historical group of ABMT patients.
Number of subjects: 37
Study 9989882 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival of patients after PBSC collection.
Number of subjects: 37
Study 7539806 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin (6,000,000 KIE)
Number of subjects: 100
Study 7539806 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 2741191 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin 900 mg every 8 h admixed with gentamicin 1.5 mg/kg every 8 h (8-h group)
Number of subjects: 21
Study 2741191 — intervention group
Group type: COMPARATOR
Intervention: Clindamycin 600 mg every 6 h given separately (6-h group)
Number of subjects: 21
Study 31567873 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg/d PhytoSERM for 12 weeks
Number of subjects: 46
Study 31567873 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg/d PhytoSERM
Number of subjects: 46
Study 31567873 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 30636738 — intervention group
Group type: EXPERIMENTAL
Intervention: Idalopirdine 60 mg/day as adjunctive therapy
Number of subjects: 1463
Study 30636738 — intervention group
Group type: EXPERIMENTAL
Intervention: Idalopirdine 60 mg/day as adjunctive therapy with memantine
Number of subjects: 1463
Study 30636738 — intervention group
Group type: EXPERIMENTAL
Intervention: Idalopirdine 60 mg/day
Number of subjects: 1463
Study 30636738 — intervention group
Group type: EXPERIMENTAL
Intervention: Idalopirdine 60 mg/day with memantine
Number of subjects: 1463
Study 28712618 — intervention group
Group type: EXPERIMENTAL
Intervention: tPA
Number of subjects: 1119
Study 28712618 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1119
Study 25316259 — intervention group
Group type: EXPERIMENTAL
Intervention: S‐1 plus oxaliplatin (SOX)
Number of subjects: 685
Study 25316259 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin plus S‐1 (CS)
Number of subjects: 685
Study 23352231 — intervention group
Group type: EXPERIMENTAL
Intervention: Dehydration-Alcohol (DA)
Number of subjects: 16
Study 23352231 — intervention group
Group type: COMPARATOR
Intervention: Dehydration-Placebo (DP)
Number of subjects: 16
Study 23352231 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial Rehydration-Alcohol (PA)
Number of subjects: 16
Study 23352231 — intervention group
Group type: EXPERIMENTAL
Intervention: Full Rehydration-Alcohol (FA)
Number of subjects: 16
Study 21255982 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol, mean dosage 4.14 mg (±1.70), duration 42.92 days (±16.85)
Number of subjects: 112
Study 21255982 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone, mean dosage 4.17 mg (±1.55), duration 42.92 days (±16.85)
Number of subjects: 112
Study 21255982 — intervention group
Group type: EXPERIMENTAL
Intervention: Early response (≥ 30% improvement in PANSS total score by week 2)
Number of subjects: 112
Study 21255982 — intervention group
Group type: EXPERIMENTAL
Intervention: PANSS positive subscore at admission
Number of subjects: 112
Study 21255982 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of untreated psychosis
Number of subjects: 112
Study 21255982 — intervention group
Group type: EXPERIMENTAL
Intervention: PANSS general psychopathology subscore
Number of subjects: 112
Study 19150366 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based counselling (A)
Number of subjects: 1948
Study 19150366 — intervention group
Group type: COMPARATOR
Intervention: Referred care (B)
Number of subjects: 1948
Study 19150366 — intervention group
Group type: COMPARATOR
Intervention: Low risk individuals
Number of subjects: 1948
Study 17717252 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP (7.5 cm H2O)
Number of subjects: 20
Study 17717252 — intervention group
Group type: COMPARATOR
Intervention: Control (ambient pressure)
Number of subjects: 20
Study 17717252 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 20
Study 14672358 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise in a lower body negative pressure (LBNP) chamber (EX/LBNP)
Number of subjects: 16
Study 14672358 — intervention group
Group type: COMPARATOR
Intervention: Sedentary control (SED)
Number of subjects: 16
Study 11180021 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 g of mycophenolate mofetil alone (study 1)
Number of subjects: 0
Study 11180021 — intervention group
Group type: COMPARATOR
Intervention: 1.0 g of mycophenolate mofetil and 2 tablets of iron ion preparations (study 2)
Number of subjects: 0
Study 9195264 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplementary nutrition (average intake of 2098 kcal/day for a total of 11 days)
Number of subjects: 32
Study 9195264 — intervention group
Group type: COMPARATOR
Intervention: Control group (32 amputees in another hospital)
Number of subjects: 32
Study 9195264 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplementary nutrition group
Number of subjects: 32
Study 9195264 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 32
Study 8479123 — intervention group
Group type: EXPERIMENTAL
Intervention: Gianturco self-expanding stent placed after percutaneous transvenous angioplasty (PTVA)
Number of subjects: 58
Study 8479123 — intervention group
Group type: COMPARATOR
Intervention: Control group (no stent placed after PTA)
Number of subjects: 58
Study 3100007 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem 120 mg
Number of subjects: 15
Study 3100007 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem 240 mg
Number of subjects: 15
Study 3100007 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem 360 mg
Number of subjects: 15
Study 3100007 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 3100007 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem (all doses)
Number of subjects: 15
Study 3100007 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem 120 mg (challenge after treatment)
Number of subjects: 15
Study 3100007 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem (sustained therapy)
Number of subjects: 15
Study 29369963 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-Basic Life Support (T-BLS) training program
Number of subjects: 24
Study 29369963 — intervention group
Group type: COMPARATOR
Intervention: Standard Basic Life Support (S-BLS) training program
Number of subjects: 24
Study 27160475 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy plus goserelin (10.8 mg goserelin by subcutaneous injection on the first day of irradiation and 3 months later)
Number of subjects: 743
Study 27160475 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone (66 Gy in 33 fractions 5 days a week for 7 weeks)
Number of subjects: 743
Study 27160475 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy plus goserelin
Number of subjects: 743
Study 27160475 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 743
Study 24428904 — intervention group
Group type: EXPERIMENTAL
Intervention: Consultation support
Number of subjects: 3906
Study 24428904 — intervention group
Group type: EXPERIMENTAL
Intervention: Consultation-plus-coaching support
Number of subjects: 3906
Study 24428904 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 3906
Study 22420772 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative sum charts
Number of subjects: 82
Study 22420772 — intervention group
Group type: COMPARATOR
Intervention: Usual teaching (Control)
Number of subjects: 82
Study 19966043 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive smoking-cessation intervention (5 counseling sessions + nicotine replacement)
Number of subjects: 56
Study 19966043 — intervention group
Group type: COMPARATOR
Intervention: Non-intervention group
Number of subjects: 56
Study 17990049 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil 10 mg per day (one patient received just 5 mg)
Number of subjects: 19
Study 17990049 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 19
Study 15777141 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient psychiatric review followed by telephone case conferencing between specialist hospital staff and GPs to provide patient‐specific information about the patient's depression and its management, educational material, and ongoing clinical support.
Number of subjects: 669
Study 15777141 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief phone advice from a psychiatrist (post hoc analysis).
Number of subjects: 669
Study 12357142 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute normovolemic hemodilution (ANH)
Number of subjects: 78
Study 12357142 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 78
Study 10621763 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (up to 60 mg/day)
Number of subjects: 53
Study 10621763 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study 8798934 — intervention group
Group type: EXPERIMENTAL
Intervention: Equipoise among patients
Number of subjects: 0
Study 8798934 — intervention group
Group type: COMPARATOR
Intervention: Clinical equipoise
Number of subjects: 0
Study 1752498 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentrated 25% albumin infusion for the first 16 hours after surgery
Number of subjects: 28
Study 1752498 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentrated 25% albumin infusion
Number of subjects: 28
Study 1752498 — intervention group
Group type: COMPARATOR
Intervention: Standard crystalloid solution
Number of subjects: 28
Study 7043498 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimozide (40‐60 mg/day)
Number of subjects: 30
Study 7043498 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol (40‐60 mg/day)
Number of subjects: 30
Study 7043498 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 30
Study 30612875 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine 0.5%/70% alcohol
Number of subjects: 49
Study 30612875 — intervention group
Group type: COMPARATOR
Intervention: Iodine 1%/70% alcohol
Number of subjects: 49
Study 30612875 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine 0.5%/70% alcohol and Iodine 1%/70% alcohol
Number of subjects: 49
Study 29411890 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored breastfeeding support including a dedicated breastfeeding support worker, personalized capacity-building approach, and a low-stimuli environment for 5 days.
Number of subjects: 14
Study 29411890 — intervention group
Group type: COMPARATOR
Intervention: Standard Baby-Friendly Initiative care only.
Number of subjects: 14
Study 26845265 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 482
Study 26845265 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 482
Study 26845265 — intervention group
Group type: COMPARATOR
Intervention: Lithium and Quetiapine (both with adjunctive personalized treatments)
Number of subjects: 482
Study 26845265 — intervention group
Group type: COMPARATOR
Intervention: Employed participants
Number of subjects: 482
Study 26845265 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater improvement in functioning and quality of life
Number of subjects: 482
Study 26845265 — intervention group
Group type: EXPERIMENTAL
Intervention: Early (8 weeks) and very early (4 weeks) clinical changes in mood symptoms
Number of subjects: 482
Study 24928472 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum under‐O‐glycosylated IgA1 levels measured by HAA-ELISA
Number of subjects: 32
Study 24928472 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum under‐O‐glycosylated polymeric IgA1 (pIgA1) measured by pIgA1 trap
Number of subjects: 32
Study 24928472 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between Area‐IgA and data from HAA‐ELISA or pIgA1 trap
Number of subjects: 32
Study 21840117 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-year screening interval (Gothenburg)
Number of subjects: 17503
Study 21840117 — intervention group
Group type: COMPARATOR
Intervention: 4-year screening interval (Rotterdam)
Number of subjects: 17503
Study 19896635 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard-fluence PDT (50 J/cm²)
Number of subjects: 42
Study 19896635 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fluence PDT (25 J/cm²)
Number of subjects: 42
Study 17698900 — intervention group
Group type: EXPERIMENTAL
Intervention: vildagliptin (100 mg) with glibenclamide (5 mg)
Number of subjects: 16
Study 17698900 — intervention group
Group type: EXPERIMENTAL
Intervention: vildagliptin (100 mg) without glibenclamide (5 mg)
Number of subjects: 16
Study 17698900 — intervention group
Group type: COMPARATOR
Intervention: glibenclamide (5 mg)
Number of subjects: 16
Study 15449048 — intervention group
Group type: EXPERIMENTAL
Intervention: 123I‐MIBG intervention
Number of subjects: 39
Study 12609779 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryotherapy plus transplantation of non-cultured melanocytes and keratinocytes (KM)
Number of subjects: 11
Study 12609779 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryotherapy plus transplantation of cultured melanocytes (CC)
Number of subjects: 11
Study 12609779 — intervention group
Group type: COMPARATOR
Intervention: Only cryotherapeutic treatment (OC)
Number of subjects: 11
Study 12609779 — intervention group
Group type: COMPARATOR
Intervention: Cryotherapy plus melanocyte culture medium (CM)
Number of subjects: 11
Study 10588768 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole (400 mg) and praziquantel (40 mg/kg body weight)
Number of subjects: 0
Study 10588768 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole and praziquantel
Number of subjects: 0
Study 10588768 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8941458 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-injection scheme (regimen A)
Number of subjects: 95
Study 8941458 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of glibenclamide with one injection of NPH insulin at bedtime (regimen B)
Number of subjects: 95
Study 8941458 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of glibenclamide with one injection of NPH insulin before breakfast (regimen C)
Number of subjects: 95
Study 8941458 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall insulin treatment
Number of subjects: 95
Study 8941458 — intervention group
Group type: COMPARATOR
Intervention: Combined insulin-sulfonylurea treatment
Number of subjects: 95
Study 1949134 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant sporozoite vaccine
Number of subjects: 25
Study 1949134 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 6119926 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipotassium clorazepate (DPCA)
Number of subjects: 300
Study 6119926 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (DP)
Number of subjects: 300
Study 6119926 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study 31706917 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week multicomponent frailty prevention program (exercise, cognitive training, board game activities)
Number of subjects: 127
Study 31706917 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week multicomponent frailty prevention program
Number of subjects: 127
Study 31706917 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 127
Study 31140114 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor pediatric tablets taken whole
Number of subjects: 44
Study 31140114 — intervention group
Group type: COMPARATOR
Intervention: Ticagrelor pediatric tablets suspended in water
Number of subjects: 44
Study 31140114 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor pediatric tablets and granules for oral suspension
Number of subjects: 44
Study 31140114 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor and its active metabolite AR‐C124910XX
Number of subjects: 44
Study 31140114 — intervention group
Group type: EXPERIMENTAL
Intervention: All formulations
Number of subjects: 44
Study 27552823 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 60
Study 27552823 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamphetamine
Number of subjects: 60
Study 27552823 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal boys)
Number of subjects: 60
Study 25730133 — intervention group
Group type: EXPERIMENTAL
Intervention: <10th percentile group
Number of subjects: 0
Study 25730133 — intervention group
Group type: COMPARATOR
Intervention: ≥10th percentile group
Number of subjects: 0
Study 25730133 — intervention group
Group type: EXPERIMENTAL
Intervention: Customized birth weight percentile
Number of subjects: 0
Study 23646469 — intervention group
Group type: EXPERIMENTAL
Intervention: Qingyang Toujie Mixture (QTM) in combination with prednisone tablet
Number of subjects: 42
Study 23646469 — intervention group
Group type: COMPARATOR
Intervention: Placebo in combination with prednisone tablet
Number of subjects: 42
Study 21123443 — intervention group
Group type: EXPERIMENTAL
Intervention: CR (25% calorie restriction)
Number of subjects: 46
Study 21123443 — intervention group
Group type: EXPERIMENTAL
Intervention: CR+EX (12.5% CR plus 12.5% increase in energy expenditure by exercise)
Number of subjects: 46
Study 21123443 — intervention group
Group type: COMPARATOR
Intervention: Control (energy intake at 100% of energy requirements)
Number of subjects: 46
Study 19180891 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractional CO2 laser treatment with density 1 settings
Number of subjects: 15
Study 19180891 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractional CO2 laser treatment with density 2 settings
Number of subjects: 15
Study 19180891 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractional CO2 laser treatment with density 3 settings
Number of subjects: 15
Study 17419458 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardioversion management principles; specific details on dosage and duration not available.
Number of subjects: 0
Study 10960627 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg norethindrone acetate/10 microg ethinyl E2
Number of subjects: 485
Study 10960627 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg norethindrone acetate/5 microg ethinyl E2
Number of subjects: 485
Study 10960627 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg norethindrone acetate/1 microg ethinyl E2, 0.5 mg norethindrone acetate/2.5 microg ethinyl E2, 1 mg norethindrone acetate/5 microg ethinyl E2
Number of subjects: 485
Study 10960627 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 485
Study 8994456 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonazepam
Number of subjects: 56
Study 8994456 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 1638587 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefprozil 500 mg once daily (or 20 mg/kg once daily) for 5 to 10 days
Number of subjects: 598
Study 1638587 — intervention group
Group type: COMPARATOR
Intervention: Cefaclor 250 mg three times daily (or 20 mg/kg daily in three equal doses) for 5 to 10 days
Number of subjects: 598
Study 6143736 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg propranolol i.v.
Number of subjects: 6
Study 6143736 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg mepindolol sulfate i.v.
Number of subjects: 6
Study 30466891 — intervention group
Group type: EXPERIMENTAL
Intervention: Custirsen added to first-line chemotherapy with docetaxel
Number of subjects: 600